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Ras proteins function in stimulating cell proliferation
and differentiation through the activation of Raf-
dependent and Raf-independent signal transduction
pathways and the subsequent activation of specific tran-
scription factors. The transcription factor NF-kB has
been widely studied as a regulator of genes involved in
immune and inflammatory responses. A variety of stim-
uli activate NF-kB through the induced phosphorylation
and degradation of the inhibitor IkB followed by nu-
clear translocation of NF-kB. We show here that onco-
genic forms of Ha-Ras activate NF-kB, not through in-
duced nuclear translocation, but rather through the
activation of the transcriptional function of the NF-kB
RelA/p65 subunit. Importantly, RelA/p65 2/2 cells are
inefficient in the activation of kB-dependent gene ex-
pression in response to oncogenic Ras expression. Fur-
thermore, IkBa expression blocks focus formation in
NIH3T3 cells induced by oncogenic Ras. These results
demonstrate that NF-kB is a critical downstream medi-
ator of Ha-Ras signaling and oncogenic potential.
Members of the Ras family of GTP-binding proteins serve as
essential mediators in the ability of a variety of extracellular
stimuli to regulate cellular proliferation and differentiation (1,
2). Oncogenic mutations in ras alleles, which occur in approx-
imately 30% of human cancers, lead to chronic GTP binding,
which initiates the activation of signal transduction cascades.
In this regard, Ras is known to stimulate both the Raf/MEK1/
ERK pathway as well as the MEKK/SEK/JNK pathway (3–7).
Activation of these and other protein kinase cascades (8–10) is
critical for the ability of Ras to exert both its normal and
oncogenic functions. The ultimate targets of the Ras-induced
signal transduction pathways are transcription factors (see
Ref. 4), which regulate the expression of genes involved in
proliferation and oncogenesis. Two transcription factors, Ets
and c-Jun, have been shown to be essential for Ras-induced
gene expression and for Ras-mediated cell transformation in
vitro and tumorigenesis (11, 12). In these cases, Ras-induced
signaling pathways activate the transcriptional function of
both Ets and c-Jun via induced phosphorylation of their tran-
scriptional activation domains (Ref. 13 and reviewed in Ref. 4).
The NF-kB family of proteins has been studied largely for the
ability of these transcription factors to regulate a variety of
genes involved in immune and inflammatory responses (re-
viewed in Ref. 14). The activation of these genes in response to
inflammatory cytokines, T cell activation signals, lipopolysac-
charide, etc. involves the targeted phosphorylation and degra-
dation of the NF-kB inhibitor IkB, allowing nuclear transloca-
tion of NF-kB (reviewed in Ref. 14). Additionally, growing
evidence indicates that NF-kB may play an important role in
controlling cellular proliferation. For example, the c-myc proto-
oncogene has been shown to be transcriptionally regulated by
NF-kB (15), and antisense inhibition of IkBa leads to cellular
transformation of NIH3T3 cells (16). Furthermore, members of
the NF-kB and IkB families are associated with chromosomal
translocations found in certain lymphomas (for example, see
Ref. 17).
We and others previously demonstrated that transient trans-
fection of oncogenic forms of Ha-Ras or of Raf-1 leads to the
activation of reporter gene expression controlled by multiple
NF-kB sites (18, 19). Consistent with the previous co-transfec-
tion studies, kB-dependent gene expression was elevated sig-
nificantly in both Ras- and Raf-transformed cells as compared
with the parental 3T3 cells. Interestingly, increased NF-kB
binding activity was not detected in the Ras- or Raf-trans-
formed cells. However, the activity of the transcriptional acti-
vation domain of the NF-kB RelA/p65 subunit was significantly
increased in these cells. p65 2/2 fibroblasts exhibited a re-
duced kB-dependent transcription response to either oncogenic
Ras or Raf but retained their ability to activate the p65/RelA
transcriptional activation domain. Finally, oncogenic Ras fo-
cus-forming activity was blocked by IkBa expression. These
data indicate that NF-kB is an important downstream target
for Ras-activated signal transduction pathways.
EXPERIMENTAL PROCEDURES
Cells and Transfections—NIH3T3 cells, the Ha-Ras and Raf-1-trans-
formed counterparts, and the p65 1/2 and p65 2/2 mouse embryo
fibroblasts were maintained in Dulbecco’s modified Eagle’s medium
supplemented with 10% calf serum, penicillin, and streptomycin. DNA
transfections were performed by the calcium phosphate precipitation
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method as described previously (18). The plasmid pGEM or salmon
sperm DNA was used to equalize the amount of DNA transfected in
each experiment to 15 mg. CAT analysis and luciferase assays were
performed as previously reported (18, 20). In all cases, 1 unit of relative
activity represents the CAT or luciferase activity obtained after trans-
fection of the reporter gene alone. All experiments were performed at
least three times with similar results.
Plasmids—The following plasmids have been described previously:
activated Raf (RafBXB) and activated Ras (v-Ha-Ras) expression vec-
tors (18), the IkBa expression vector (21), the super-repressor IkBa
expression vector (22), the expression vector encoding the Gal4 DNA-
binding domain fused to the C-terminal domain of p65/RelA
(Gal4p65aa519–551 (23)), the reporters 3X-kB-CAT and 3X-mutkB-
CAT (18), the HIV LTR-CAT and HIV-DkB-CAT reporters (18), 5X-
Gal4-CAT (24), and DHFR-CAT (25).
Extracts and Gel Mobility Shift Assays—Nuclear and cytoplasmic
extracts were prepared as described previously (26). For double sucrose
pad purification, washed nuclei were resuspended in lysis buffer lack-
ing Nonidet P-40 and layered on a sucrose pad (30% sucrose, 60 mM
KCl, 15 mM NaCl, 15 mM Hepes, 2 mM EDTA, 0.75 mM spermidine, 0.15
mM spermine, and 1 mM dithiothreitol) and centrifuged for 15 min at
3,000 rpm in an HB4 rotor. The sucrose pad was then removed, the
nuclei resuspended, and the process repeated. Nuclear extracts were
then prepared from the sucrose pad-purified nuclei. Gel mobility shift
assays (EMSAs) were performed as described previously (26).
Focus Formation Assays—NIH3T3 cells were transfected by calcium
phosphate coprecipitation essentially as described (27). For each 60-mm
plate, 10 ng of Ras expression vector pZip-rasH(61L) was transfected,
along with the indicated quantity of IkBa expression vector or empty
vector. In all cases, the expression vector was normalized with the
cognate empty expression vectors. Cells were fed every 2 days, and the
appearance of foci of transformed cells was counted 14 days after
transfection. Four plates per condition were transfected, and graphs
represent the mean 6 S.E. of these counts. Data are representative of
four independent experiments performed in quadruplicate.
RESULTS
Oncogenic Ras- or Raf-transformed Cells Exhibit Increased
kB-dependent Transcription without Increased Nuclear Accumu-
lation of NF-kB—Previous transient cotransfection experiments
indicated that expression of either oncogenic Ras or oncogenic
Raf led to a significant activation of expression of a kB-dependent
reporter (18). Consistent with the previous cotransfection data,
the activity of a kB-dependent reporter was significantly elevated
in both Ras- and Raf-transformed cells but not in the parental
NIH3T3 cells (Fig. 1A). A reporter mutated in the NF-kB sites did
not exhibit this enhanced activity, and expression of the NF-kB
inhibitor IkBa blocked the Ras- and Raf-induced activation of
kB-dependent reporter activity, indicating that NF-kB regulates
the transcription response. A similar result was obtained with
the NF-kB-dependent HIV-LTR reporter (data not shown). Addi-
tionally, expression of the non-Ras-responsive DHFR-CAT re-
porter was approximately equivalent in each of the three cell
types (data not shown) showing that the differential responses
observed in the transformed cells were not due to differential
uptake of plasmids.
To determine if oncogenic Ras as well as oncogenic Raf acti-
vated nuclear accumulation of NF-kB, gel mobility shift assays
(EMSAs) were performed with nuclear extracts from parental
NIH3T3 cells, oncogenic Ras-transformed NIH3T3 cells, or
Raf-transformed NIH3T3 cells. To demonstrate that binding
activity was exclusively nuclear, extracts were prepared from
double sucrose pad-purified nuclei. Immunoblotting for NF-
kB1/p105 (which is cytoplasmic) indicated that there was no
cytoplasmic contamination in the nuclear preparations (data
not shown). As shown in Fig. 2, NF-kB was detected in the
nuclei of each of the different cells at similar levels. Antibody
“supershift” experiments showed that this binding activity is
authentic, p65/RelA-containing NF-kB (data not shown). These
results were surprising and indicated that the activation of
kB-dependent transcription observed in the transfection exper-
iments shown in Fig. 1 was not controlled by the induced
nuclear accumulation of NF-kB but suggested that this re-
sponse was mediated by the relatively low levels of constitu-
tively nuclear NF-kB in NIH3T3 fibroblasts. It should be noted
that transient transfection of oncogenic Ras into 3T3 cells or
the induction of oncogenic Ras in Rat-1 cells led to an approx-
imate 3-fold increase in nuclear NF-kB (data not shown); how-
ever established Ras-transformed cells did not exhibit this
property. These experiments indicated that oncogenic Ras or
Raf can activate kB-dependent transcription without enhanc-
ing nuclear levels of NF-kB.
Oncogenic Forms of Ras and Raf Activate the Transcriptional
Function of NF-kB p65/RelA—To explain the activation of kB-
dependent transcription by oncogenic forms of Ras or Raf without
an induction of NF-kB nuclear translocation, we asked whether
the transcriptional activation function of NF-kB was stimulated
FIG. 1. kB-dependent gene expression is increased in Ras- as
well as Raf-transformed cells. Either the kB-dependent CAT re-
porter (3X-kB-CAT) or its mutant version (3X-kBmut-CAT) was trans-
fected into Ras-transformed NIH3T3 cells, Raf-transformed NIH3T3
cells, or parental NIH3T3 cells either alone or with the CMV-IkBa
expression vector. CAT activity was measured as described under “Ex-
perimental Procedures.” Data are presented as mean 6 S.D.
FIG. 2. NF-kB binding activity is not increased in Ras- or Raf-
transformed NIH3T3 cells. Gel mobility shift assays were performed
on extracts of double sucrose pad-purified nuclei from parental NIH3T3
cells or the Ras- and Raf-transformed counterparts as described under
“Experimental Procedures.” NF-kB is shown by the arrow.
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in the transformed cells. A plasmid (Gal4p65) encoding a fusion
of the C-terminal (TA1) transactivation domain of RelA (23) with
the DNA-binding domain of the yeast transcription factor Gal4
was transfected into parental NIH3T3 cells, or Ras- or Raf-
transformed cells, along with a luciferase reporter containing
upstream Gal4-binding sites. Luciferase activity driven by
Gal4p65 or Gal4 was compared in the three cell types. The
results indicate that the Gal4p65 construct is strongly active in
the Ras- and the Raf-transformed cells but only weakly active in
the untransformed 3T3 cells (Fig. 3A). EMSA experiments indi-
cated that there was not an increase in the DNA binding activity
of the Gal4-p65 protein in the Ras- and Raf-transformed cells
(data not shown). These results demonstrate that oncogenic Ras
or Raf activates a signal transduction pathway that stimulates
p65/RelA transcriptional activation function controlled by the
TA1 transcriptional activation domain.
The results described above suggested that the RelA subunit
of NF-kB may function as a critical downstream transcriptional
effector for the Ras oncoprotein. To test this hypothesis, we
utilized immortalized RelA 1/2 and RelA 2/2 embryonic fi-
broblasts (28) for transfection and gene expression studies.
Oncogenic Ras was ineffective at activating kB-dependent gene
expression in the p65 2/2 cells (approximately a 2-fold activa-
tion), whereas effective Ras activation of kB-dependent gene
expression (approximately 7-fold) was observed in the RelA
1/2 cells, as expected (Fig. 3B). To show that the Ras-respon-
sive signal transduction pathway was still operative in the
RelA 2/2 cells, the Gal4p65 construct was cotransfected with
either activated Ha-Ras or activated Raf-1. Ras activated the
Gal4p65 construct as effectively in RelA 1/2 cells as in RelA
2/2 cells. These results demonstrate that the RelA/p65 sub-
unit of NF-kB is required for oncogenic Ras to effectively acti-
vate gene expression driven by consensus NF-kB-binding sites.
NF-kB Is Required for Ras-mediated Cellular Transforma-
tion—To determine whether NF-kB is required for cellular
transformation controlled by oncogenic Ha-Ras, we determined
whether the inhibition of NF-kB would affect the ability of Ras
to cause formation of transformed foci in cultured NIH3T3
cells. To specifically inhibit NF-kB activity, we used an expres-
sion vector encoding IkBa, which can enter the nucleus and
relocate NF-kB to the cytoplasm (29). Transfection of pZIP-
ras(61L) together with the empty CMV vector yielded an aver-
age of approximately 160 foci/plate (Fig. 4). Co-expression of
oncogenic Ras with wild-type IkBa blocked focus formation
activity by greater than 50%. Co-expression with a super-re-
pressor form of IkBa (mutated in serines 32 and 36) that is
unable to be inducibly phosphorylated or degraded in response
to stimuli (see Ref. 22) blocked focus formation by approxi-
FIG. 3. The p65/RelA subunit of NF-kB is functionally activated
by Ras and is required for Ras to efficiently activate kB-depend-
ent gene expression. A, either the vector (Gal4p65) encoding a fusion
protein between the DNA binding of Gal4 and the TA1 transcriptional
activation domain of p65/RelA or the Gal4 vector was transfected into
NIH3T3 cells or the Ras- or Raf-transformed counterparts of these cells.
CAT activity was determined as described under “Experimental Proce-
dures.” B, SV40 large T (Tag) immortalized embryonic fibroblasts iso-
lated from p65 2/2 or p65 1/2 mice were transfected with the kB-de-
pendent CAT reporter alone with oncogenic Ras or with the Gal4p65
vector alone or with oncogenic Ras. CAT activity was measured as
described and is presented as mean 6 S.D.
FIG. 4. IkBa blocks focus formation induced by oncogenic Ras.
NIH3T3 cells were transfected with the oncogenic Ras expression vector
(plus empty CMV vector) or with the empty vector Ras expression
vector. Alternatively, the Ras expression vector was co-transfected with
a vector encoding the wild-type form of IkBa or a vector encoding the
modified, super-repressor form of IkBa (IkBa(AA)) as described under
“Experimental Procedures.” Results are presented as foci per plate and
are the mean 6 S.D.
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mately 70–75% (Fig. 4). Expression of IkBa did not block ex-
pression of the promoter driving Ras expression or Ras protein
expression (data not shown). Interestingly, IkBa was unable to
block the ability of activated Rho (Rho63L) to induce focus
formation. In these experiments, activated Rho yielded approx-
imately 20 foci/plate, and IkBa expression did not reduce this
number of foci (data not shown).
DISCUSSION
The data presented here indicate that oncogenic ras alleles
activate NF-kB-dependent transcription, not through the in-
duced nuclear translocation of NF-kB, but rather through the
stimulation of the transcriptional activation function of NF-kB
via the targeting of the RelA/p65 subunit. Furthermore, the
data indicate that NF-kB is required for Ras to initiate efficient
cellular transformation and that NF-kB plays a role in medi-
ating certain essential aspects of cellular transformation. Thus,
NF-kB joins Ets family members (13) and c-Jun (4, 12) as
downstream targets of oncogenic Ras that are required for
Ras-mediated cellular transformation.
How does Ras activate NF-kB functional activity? Our data
strongly indicate that the transcriptional activation function of
RelA/p65 NF-kB is potentiated in both Ras- as well as Raf-
transformed cells, and at least two mechanisms exist to explain
this phenomenon. First, a Ras-initiated signal transduction
pathway may target the p65 transcriptional activation domain
for phosphorylation, which may allow enhanced interactions
with a transcriptional co-activator or with basal transcriptional
machinery. Such a mechanism appears to be operative for both
Ets-1 and -2 and for c-Jun (4, 13). A second mechanism may be
that a transcriptional co-activator is modified such that it in-
teracts functionally with p65 transcriptional activation do-
main. Also of importance is identification of the signal trans-
duction pathway that is initiated by Ras to stimulate NF-kB
transcriptional activity. Since both oncogenic Ras as well as
oncogenic Raf stimulate kB-dependent activity, it may be as-
sumed that the relevant pathway is downstream of Raf and is,
therefore, the MEK/ERK pathway. However, inhibitors of this
pathway did not block the ability of Ras to activate kB-depend-
ent transcription, and dominant negative forms of kinases in
the SEK/JNK pathway were able to block this response.2 Thus
the ability of Raf to activate kB-dependent gene expression in a
MEK/ERK-independent pathway may be explained by the re-
cent observation that Raf stimulates JNK activity via an auto-
crine mechanism (30).
Prior studies have shown that the major regulatory mecha-
nism involved in regulating kB-dependent transcription is in-
duced nuclear translocation (see Ref. 14). Our data indicate
that significant kB-dependent transcription can be realized
without enhancing the constitutive, low nuclear levels of NF-
kB. This suggests that under some circumstances the func-
tional activity of NF-kB can be separated from induction of
nuclear translocation. Consistent with this concept are the
recent observations that the tyrosine kinase inhibitor genistein
blocks the ability of NF-kB to stimulate transcription of an
NF-kB-dependent reporter but is not able to block nuclear
translocation of NF-kB (31) and that phorbol 12-myristate 13-
acetate can activate the TA2 transcriptional activation domain
of RelA/p65 (23).
Evidence that NF-kB is required for Ras-mediated cellular
transformation is consistent with several observations indicat-
ing a role for NF-kB in controlling cell growth. First, it has been
shown that NF-kB can regulate c-myc gene expression. Second,
antisense studies indicate that NF-kB can control oncogenesis.
These experiments utilized antisense to p65 to block oncogene-
controlled transformation (32, 33) and antisense to IkBa to
induce transformation of NIH3T3 cells (16). Additionally, other
oncogenes such as Her2/NEU are known to activate NF-kB
(34). Thus, the activation of NF-kB may be common to a num-
ber of oncogenes, particularly those that utilize Ras-controlled
signaling pathways. Additionally, we have been able to show
NF-kB activation is required to block a Ras-induced apoptotic
response.3 This result is consistent with recent data (22,
35–38) that NF-kB activation can block the induction of apo-
ptosis. Further experiments are required to establish the exact
role that NF-kB plays in controlling Ras-mediated oncogenesis.
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